HROW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harrow Inc. (HROW) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. Despite near-term pricing uncertainties, the company's growth potential in the ophthalmic drug market, strong analyst support, and upcoming catalysts make it a promising long-term investment.
The MACD histogram is positively expanding at 1.081, indicating bullish momentum. RSI_6 is at 86.567, signaling overbought conditions, which may suggest a short-term pullback. Moving averages are converging, and the stock is trading near resistance levels (R2: 43.993).
Strong growth potential in multi-billion-dollar ophthalmic drug markets.
Projected revenue growth of 36% YoY in 2025 with EBITDA expected to rise 54%.
Analyst price targets suggest an 86% upside over the next 12 months.
Upcoming commercial and pipeline catalysts.
Near-term pricing uncertainty for key products like VEVYE.
Overbought RSI suggests potential short-term pullback.
No significant hedge fund or insider trading trends.
Financial data unavailable for the latest quarter. However, revenue is projected to grow significantly in 2025, indicating strong future performance.
Analysts maintain a positive outlook with Buy and Overweight ratings. Price targets have been revised downward recently (e.g., $60 from $65 by B. Riley and $88 from $91 by Cantor Fitzgerald) due to near-term pricing challenges, but they remain optimistic about long-term growth prospects.
